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ABSTRACT 
Objective: Depression and socioeconomic disadvantage are linked to all-cause mortality but the potential underlying biological mechanisms are unknown. 
Inflammatory and neurohormonal biomarkers may mediate the relationship between depressive symptoms and mortality.  
Methods: We used Cox proportional hazards modelling to examine the association between depression, measured by the 10-item Welsh Pure Depression 
Inventory, in 2389 men from the Belfast PRIME prospective cohort aged 50-59 years, and mortality (418 deaths) during 18 years of follow-up. In addition, 
we examined the potential mediating influence of biomarkers of neurohormonal function {N-terminal Pro-brain natriuretic peptide (NTProBNP), mid-region 
pro-atrial natriuretic peptide (MRProANP), mid-region Pro-adrenomedullin (MRProADM), c-terminal pro-endothelin-1 (CTProET)} and inflammatory status 
{C-reactive protein (CRP), Neopterin, Interleukin-1 receptor antagonist (IL1Ra) and Interleukin-18 (IL18)} on any excess mortality associated with 
depression.  
Results: Higher levels of depressive symptoms and lower socioeconomic circumstances (manual occupation, fewer years of education, poorer material 
conditions), were associated with higher levels of CRP, IL1Ra and CTProET. After adjustment for socioeconomic and lifestyle risk factors, depressive 
symptoms significantly predicted all-cause mortality, a 1 point higher score on depressive symptoms being associated with hazard ratio of 1.10, (95% 
confidence interval 1.04-1.16). The proportion of depressive symptoms’s effect on mortality explained by CRP was 7.3% suggesting a minimal mediation 
effect. Individually, CRP, IL1Ra, NTProBNP, MRProANP, MRProADM and CTProET, contributed very marginally to the effect of depression on mortality.  
Conclusions: Inflammatory and neurohormonal biomarkers are associated with depression and with increased mortality but may contribute an additive 
effect rather than mediating this relationship.  
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Abbreviations:  
NTProBNP: N-terminal Pro-brain natriuretic peptide  
MRProANP: mid-region pro-atrial natriuretic peptide 
MRProADM: mid-region Pro-adrenomedullin  
CTProET: c-terminal pro-endothelin-1 (CTProET) 
CRP C-reactive protein 
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IL1Ra Interleukin-1 receptor antagonist 
IL18: Interleukin-18 
SES: socioeconomic status 
HDL cholesterol: High density lipoprotein cholesterol 
HPA axis: hypothalamic pituitary adrenal axis 
BMI: body mass index 
HR: hazard ratio 
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INTRODUCTION 
In population based studies, depression has been related to a 1.4 fold excess risk of all-cause mortality.[1] Symptoms of depression and anxiety 
(psychological distress) occur in around 7.5% of the general population [2] and range along a continuum of severity. In one study, even participants with 
minor levels of symptoms (as indicated by low scores on the General Health Questionnaire scale of psychiatric morbidity) were at increased risk of mortality 
from all causes including cardiovascular disease.[2] This suggests that an association between depression and mortality exists well below the threshold that 
would lead to a diagnosis of depression that would require specific treatment. It is important to note that there are difficulties in capturing depressive 
symptoms in population based studies and the associated methodological challenges can affect estimates of prevalence and risk.[3]  
Disparities in income, occupation and education are associated with psychopathologies including mood disorder, and with unhealthy behaviours such as 
smoking and excess alcohol intake. In turn, these phenomena have been shown to associate with variation in all-cause and disease specific mortality.[2, 4] 
Several plausible mechanisms in the biological domain may explain, in part, how depression may lead directly or indirectly to poor health and higher 
mortality risk. Adverse metabolic changes may be a mediating mechanism for long term psychosocial stress and depression which might be expected to 
manifest in higher cardiovascular and mortality risk.[5] Some research suggests that depression may lead to a dis-regulation of the hypothalamic-pituitary-
adrenal (HPA) axis resulting in increased levels of inflammatory cytokines and cortisol release.[5] Such symptoms are associated with an altered autonomic 
function response to stressors and can also cause changes in neurohormonal markers such as cortisol and epinephrine, though notably they are difficult to 
measure reliably.[6] Novel blood neurohormonal biomarkers such as N terminal pro-Brain natriuretic peptide (NTProBNP) and Midregion pro-
Adrenomedulin (MRProADM) are related to cortisol and ephinephrine [6] and have been previously linked with clinical depression.[7-9] MrProADM is 
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produced by various cell types and is involved in electrolyte homeostasis and HPA axis regulation [Akpinar et al. 2013; Armstead et al. 2010]. The potential 
roles of these markers in relation to depression have received only limited research attention. Mid-region pro atrial natriuretic peptide (MRproANP) is 
closely related to NTProBNP and both are released by cardiac myocytes to promote diuresis and vasodilation. These natriuretic peptides also demonstrate 
anxiolytic behaviour, animal and human studies suggest that these natriuretic peptides partially surpress the HPA axis [Strohle et al 00, Wiedemann ’00, ‘01 
Hermann- Linger ’03, Meyer et al. ‘15]. C-terminal pro Endothelin-1 is a vasoconstrictor produced by endothelial and vascular smooth muscle cells, it can 
increase pro-inflammatory cytokine levels such as interleukins (Interleukin-18 (IL18) and Interleukin-1 receptor antagonist (IL1Ra) [Hong et al. 2006, 
Yammine et al. 2014]. Of these neurohormonal biomarkers, only NTProBNP has previously been tested for association with psychosocial/SES factors in a 
community based context.[16] IL18 and IL1Ra are cytokines which are immunomodulatory. IL1RA decreases the inflammatory response by antagonising the 
action of proinflammatory cytokines at the receptor level and is reported to be more stable than its derivative IL1. These biomarkers perform similar 
functions to IL6 and ICAM-1 which were previously examined in French PRIME cohorts.[13] Neopterin is a chemokine released in response to Interferon 
gamma and can cause a cell mediated immune response. CRP is an acute phase protein released in response to cytokines and has been previously 
examined for its association with depression in PRIME and more widely in other psychosocial research [5, Howren et al. 2009]. The relationship between 
CRP, depression and its effect on the risk of chronic disease has been explored [Vaccarino et al. 2007, Hamer et al. 2008, Surtees et al. 2008, Empana et al. 
2013. 
In this study we investigate the role of biomarkers as mediators in the relationship between depression and mortality. Chronic experience of low 
socioeconomic status including enduring financial hardship or insecurity, marginalisation or social exclusion may affect people’s mood and stress levels and 
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lead to long term psychological distress which consequently impact on biological health.[10] Chronic long term psychosocial stress may accumulate over a 
lifetime, and the effects may become more evident in middle aged populations, as their risk of all-cause morbidity and mortality increases.[11] The PRIME 
Study is a prospective cohort of middle-aged men in three centres across France and a centre in Belfast, Northern Ireland.[12] Depressive symptoms have 
been evaluated in the entire PRIME cohort.[3, 13] Previous research from the French cohorts has shown a link between depressive symptoms, 
inflammatory biomarkers C-reactive protein, Interleukin-6 and ICAM-1 and cardiovascular disease.[13] This study extends this research using the Belfast 
cohort to investigate the relationships between measures of depression and socio-economic status (e.g. work type, level of education and material 
disadvantage) with inflammatory and novel neurohormonal and vascular function biomarkers and to determine the extent to which the relationship 
between depression and mortality risk may be mediated by levels of these biomarkers while viewing socioeconomic status as a confounding variable.  
 
METHODS 
Study design 
PRIME Belfast is one of four cohorts in the PRIME study and consists of 2744 men aged 50-59, recruited from industries and various employment groups 
with broadly similar social class structures to cohorts in France, who were examined for the presence of a wide range of cardiovascular risk factors at 
baseline in 1991-93 and followed up for 18 years for cardiovascular disease and all-cause mortality.  Cardio-metabolic risk factors (e.g. cholesterol, systolic 
BP) and medication use were determined at baseline through standardised interviews, self-administered questionnaires and medical examinations, 
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informed consent was given by all participants.[14] Follow-up to January 2012 was achieved by contacting subjects annually by letter and conducting 
routine searches of a mortality register (managed by the regional public health service’s Business Services Organisation). The study was approved by the 
Research Ethics Committee, Queens University Belfast. Death certificates were searched for supporting clinical and post-mortem information on cause of 
death, and all death records were independently evaluated by a medical committee.  
Biomarker measurement 
A non-fasting blood sample was collected at baseline and serum stored for future use. Biomarkers were measured in 2009 from frozen specimens at the 
MORGAM Biomarker Laboratory, Mainz, Germany, whose assessment procedures and details have been described elsewhere.[15] Inflammatory markers 
include high sensitive CRP, IL18, IL1RA and Neopterin.  Markers of neurohormonal activity and vascular function include NTProBNP, MRProANP MRProADM 
and CTProET  
Depressive symptoms 
Depressive symptoms were assessed using 10 questions from a validated 15 item questionnaire – the Welsh Pure Depression Inventory [17] - completed at 
baseline. Question responses (true/false scored as 1/0) were summed to a single depression score scaled between 0 and 10, where higher scores denote 
more symptoms of depression.  The Cronbach’s alpha for the 10 items is 0.71, the 10 items have not been formally validated but demonstrated high face 
validity and follow expected relationships with CHD/mortality [Empana et al. 2013, ]. For analysis, we used depression as a continuous scale and categorical 
variable divided into fourths (0, 1, 2-3, 4-10).   
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Socioeconomic and lifestyle variables 
Education level was categorised into low (<12 years), medium (12-14 years) and high (15+ years) according to the number of years of full-time education. 
Work type was divided into manual or non-manual occupations. Material living conditions were measured by an aggregate of home ownership, the number 
of household bathrooms and cars divided into three categories [14]. Low material condition was defined by rental accommodation with one or fewer cars, 
baths/showers or toilets. High material condition was defined as home ownership, 2 or more cars either 2 or more baths/showers or 2 or more toilets, the 
remaining subjects were classified as living in mid-range material conditions. Lifetime smoking was categorised based on past and present smoking (never 
smoker, ≤15 pack years, >15, ≤30 pack years or >30 pack years.[18] Alcohol was explored across five categories (non drinkers, 0.1-228ml/week, 129-
265ml/week, 266-441ml/week, ≥442ml/week).  Body mass index (BMI) can mediate the relationship between depression and mortality [Howren et al. 
2009] was defined as normal weight <25kg/m2, overweight 25-30kg/m2, obese >30kg/m2. Physical activity can partially mediate the relationship between 
depression and mortality [Whooley et al. 2008, Hamer et al. 2011, Win et al. 2011], thus PA was included as a covariate, defined as the total amount of time 
spent at leisure physical activity and occupational physical activity including travel to and from work expressed in MET hours/week, examined in quartiles 
(0-62.22, 62.23-116.90, 116.91-528.0), derived from the MOSPA-Q and available for 69.3% of participants [Wagner et al. 2003].  
Statistical Analysis 
Analysis was restricted to men without cardiovascular disease at baseline (determined by self-report and validated with medical records). Of the 2744 
PRIME Belfast men, 355 (12.9%) were excluded that had cardiovascular disease at baseline. Biomarkers had varying proportions of missing values due to 
sample unavailability or other technical reasons. Missing data was handled through multiple imputation models which included all biomarkers, risk factors, 
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follow-up time and vital status at the end of follow-up (see supplementary material). Missing biomarker values varied across biomarkers (11.9-25.8% 
Supplementary Table 1), and 54 men had missing data on the depression score, with this data appearing to be missing at random. There were only small 
differences in results for complete case and imputed results (presented in supplementary table 2) but results were consistent so multiple imputed results 
are presented. Quantitative baseline characteristics were summarised as means and standard deviations, all biomarkers were log transformed to 
approximate normal distributions and summarised using geometric means and interquartile ranges. Biomarker values were compared between depressive 
symptoms and socieconomic factors by one way analysis of variance and large samples z-tests. As this is an explorative study no adjustment for multiple 
testing was performed and due to the large number of tests, p-values should be interpreted with caution and in connection with effect estimates. 
Spearman’s rank correlation coefficients were used to assess associations between biomarkers and other variables.  
Cox proportional hazards analysis provided hazard ratios (HR) and 95% confidence intervals (CI) associated with depressive symptoms, biomarkers and all-
cause mortality. Multivariable model 1 included age and depressive symptoms; model 2 additionally included social risk factors (material condition, 
education level, work type) while model 3 included also lifestyle related risk factors, lifetime cigarette smoking, alcohol consumption, body mass index 
(BMI), systolic BP and each single biomarker. The residual percentage contribution of individual biomarkers to depressive symptoms after adjustment for 
age, social and lifestyle factors was estimated using the expression 100 (bo-b1/bo) where bo is the coefficient for depression on the log hazard scale in the 
Cox regression model without biomarkers and b1 is the coefficient in the corresponding model adjusted for each biomarker.[19]  Multiple Imputation was 
carried out in STATA (release 11 (StataCorp, College Station, TX, USA), 20 rounds were performed and the resulting dataset was imported and analysed in 
SPSS version 21 (IBM Inc., Armonk, NY, USA). The imputation model incorporated a linear regression for log transformed biomarkers and HDL cholesterol, 
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an ordered logistic regression for depression, material condition, alcohol, pack years and BMI and a logistic regression for work type, history of diabetes and 
status at start and end of follow-up. Also included in the imputation equations were the follow-up time and status at the end of follow-up (more 
information available in supplementary material).   
RESULTS 
The study comprised 2389 middle-aged men and 418 deaths over 18 years of follow up. The presence of depressive symptoms as categorised by a high 
baseline depression score (range 4-10) was apparent in 12.9% of men (308/2389), and was more frequently observed in cases (death from any cause) than 
in non-cases (15.8 versus 11.2% p<0.001).  Mean values on all risk factors were different between cases and non-cases (Table 1).  
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Table 1 Descriptive statistics for men free of cardiovascular disease at baseline presented by status at follow-up. Values are mean (SD), geometric mean 
(first quartile, third quartile) or Numbers (%). 
 
 
All     
(N=2389) 
Dead 
(N=418) 
Alive 
(N=1971) p value 
Age, years 54.7 55.8 54.5 <0.001 
Current smokers (%) 545 (22.8) 170 (40.7) 375 (19.1) <0.001 
Alcohol consumption 
(ml/wk) 157.0 (6.2) 219.8 (20.8) 143.9 (6.0) <0.001 
Diabetes history (%) 40 (1.7) 18 (4.3) 22 (1.1) <0.001 
Low material condition (%) 904 (37.8) 192 (45.9) 712 (36.1) 0.006 
Manual worker (%) 1299 (54.4) 270 (64.6) 1029 (52.2) <0.001 
Low education level (%) 669 (28.0) 145 (34.7) 524 (26.6) <0.001 
Depression score (mean, SD) 1.44 (1.7) 1.77 (1.9) 1.38 (1.7) <0.001 
Depression score ≥4 (%) 308 (12.9) 66 (15.8) 221 (11.2) <0.001 
CRP (mg/L) 1.6 (0.8-3.0) 2.19 1.48 <0.001 
IL18 (pg/mL) 282 (200-363) 288 282 0.43 
IL1Ra (pg/mL) 240 (159-316) 263 234.4 <0.001 
Neopterin (nmol/L) 5.89 (4.8-6.9) 6.17 5.75 0.001 
NTProBNP (pg/mL) 29.5 (15.8-50.1) 39.8 27.5 <0.001 
MRProANP (pmol/L) 63.1 (50.1-79.4) 67.6 63.1 0.013 
MRProADM (nmol/L) 0.45 (0.4-0.5) 0.47 0.44 <0.001 
CTProET (pmol/L) 49.0 (42.5-54.7) 51.7 48.5 <0.001 
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Linear correlations between biomarkers, depressive symptoms and lifestyle risk factors are given in Table 2. Inflammatory markers were mutually but not 
strongly correlated (coefficients ranged from 0.13 to 0.32). Neurohormonal biomarkers were mutually correlated (coefficients ranged from 0.13-0.60) with 
strongest correlations between NTProBNP and MRProANP (0.60) and MRProADM and CTProET (0.57). A very low but statistically significant correlation was 
observed between depressive symptoms and inflammatory markers (ranging from 0.04 to 0.08 for CRP, Neopterin and IL1Ra) and neurohormonal markers 
(ranging from 0.04 to 0.09 for MRProADM, CTProET and NTProBNP) (Table 2).  
Higher levels of CRP, IL1Ra, Neopterin, NTProBNP, MRProADM and CTProET were significantly but weakly associated with higher levels of depressive 
symptoms expressed as continuous and categorical variables (Table 3) while MRProANP and IL18 showed no significant association. Higher levels of CRP, 
IL1Ra and CTProET were also associated with manual work, low materialconditions and less education. NTProBNP and MRProADM levels were higher for 
lower material conditions but not for manual work or education. Higher levels of MRProANP and Neopterin were significantly associated with manual work 
and education levels, while IL18 levels were not significantly associated with any socioeconomic traits. Socioeconomic status, education and work type play 
a role in the association between depressive symptoms and mortality but are subsequently viewed as a confounding influence used for adjustment rather 
than considered in terms of their own importance.  
In a Cox Proportional hazards model based on 418 deaths, a 1 unit increase in depressive symptoms was associated with a 10% increased risk of all-cause 
mortality after adjustment for social and lifestyle risk factors (Table 4). When inflammatory or neurohormonal markers were individually added, the HR for 
depressive symptoms was reduced only marginally from 1.10 to 1.09 for its association with all-cause mortality (first column of Table 4). Six of the eight 
biomarkers (CRP, IL1Ra, NTProBNP, MRProANP, MRProADM and CTProET) remained significantly predictive of mortality in these models) (second column of 
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Table 4). For five of these six biomarkers there was a significantly increased mortality risk in the top quarters of the biomarkers distribution compared with 
the bottom quarter following similar adjustment (third to sixth columns of Table 4). In these models, none of the social risk factors remained significant 
after adjustment for lifestyle variables (Table 5). BMI may act as a mediator in the association with all-cause mortality and CRP, IL1Ra and MRProADM. For 
example in the fully adjusted models without CRP, the HR for BMI is 0.85 (95% C.I. 0.73, 0.99, p=0.045) which decreases to HR 0.82 (95% C.I. 0.70, 0.96, 
p=0.015) with the addition of CRP. 
The residual percentage contribution of individual biomarkers to all-cause mortality was small and ranged from 0% (IL18) ADM) to 9.4% (CTProET) (Table 4). 
The effect of CRP as a mediator explained 7.3% of the relationship between depression and all-cause mortality after adjustment for all other risk factors.  
Insulin resistance may dysregulate homeostatic mechanisms affecting associations between these biomarkers and depressive symptoms. A sensitivity 
analysis excluded 40 participants with a history of diabetes at baseline from the analysis, in addition 18 deaths due to trauma (no 
inflammatory/neurohormonal basis) and those with CVD at baseline were excluded. Cox models were adjusted for age, depressive symptoms, social and 
lifestyle risk factors and biomarkers (Supplementary table XXX). Hazard ratios for CRP and IL1Ra marginally increased compared to the larger dataset 
suggesting that diabetes potentially obscured the effect of these biomarkers, but overall results remained similar.  
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Table 2 Spearman rank correlation coefficient matrix between continuous biomarkers, depressive symptoms, socioeconomic and lifestyle variables.  
 
 
CRP IL18 IL1Ra Neopterin NTProBNP MRProANP MRProADM CTProET depres sym SBP HDLc BMI 
CRP - 
           IL18 0.18*** - 
          IL1Ra 0.32*** 0.27*** - 
         Neopterin 0.20*** 0.14*** 0.12*** - 
        NTProBNP 0.11*** 0.02 0.03 0.14*** - 
       MRProANP -0.06** -0.02 -0.09** 0.14*** 0.6*** - 
      MRProADM 0.25*** 0.11*** 0.22*** 0.25*** 0.19*** 0.25*** - 
     CTProET 0.21*** 0.13*** 0.16*** 0.23*** 0.13*** 0.18*** 0.58*** - 
    depress sym 0.08*** -0.01 0.06** 0.04 0.04 -0.03 0.05 0.09*** - 
   systolic BP 0.15*** 0.02 0.12*** 0.01 0.11*** 0.02 0.12*** 0.08*** -0.01 - 
  HDL cholesterol -0.19*** -0.16*** -0.23*** -0.11*** 0.03 0.11*** -0.07** -0.06** -0.02 -0.03 - 
 BMI 0.26*** 0.09*** 0.26*** 0.05* -0.08*** -0.11*** 0.24*** 0.11*** -0.01 0.28*** 0.25*** - 
Physical activity -0.05 0.01 -0.03 -0.02 -0.03 0.02 -0.11*** -0.09*** -0.09*** 0.01 0.09*** -0.01 
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Table 3 Biomarkers compared in depressive and socioeconomic groups using ANOVA tests or ANOVA tests for trend on log transformed values.   
Depressive and SES risk 
factor   CRP IL18 IL1Ra Neopterin 
Depression  (N) 
geometric 
mean p value 
geometric 
mean p value 
geometric 
mean p value 
geometric 
mean p value 
Depression score 0 975 1.48 
<0.001 
288.4 
0.836 
234.4 
0.003 
5.75 
0.012 
Depression score 1 522 1.51 281.8 234.4 5.89 
Depression score 2-3 584 1.62 275.4 245.5 5.89 
Depression score 4-10 308 2.04 288.4 257.0 6.17 
Depression (continuous)  2389 1.60 <0.001 281.8 0.521 239.9 <0.001 5.89 0.005 
          Work 
         manual work 1299 1.82 
<0.001 
288.4 
0.064 
257.0 
<0.001 
6.03 
<0.001 
non-manual work 1090 1.38 275.4 218.8 5.75 
          Material conditions 
         low 908 1.82 
<0.001 
288.4 
0.871 
251.2 
<0.001 
5.89 
0.829 medium 521 1.58 288.4 239.9 5.89 
high 960 1.41 281.8 229.1 5.89 
          Years full time education 
         <12 years 669 1.73 
<0.001 
288.4 
0.174 
257.0 
<0.001 
6.03 
0.004 12-14 years 793 1.85 281.8 257.0 5.89 
15+ years 927 1.34 281.8 218.8 5.75 
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Table 3 continued.  
Depressive and SES risk 
factor   NTProBNP MRProANP MRProADM CTProET 
Depression  (N) 
geometric 
mean p value 
geometric 
mean p value 
geometric 
mean p value 
geometric  
mean p value 
Depression score 0 975 27.5 
0.042 
64.6 
0.254 
0.43 
0.024 
47.4 
<0.001 
Depression score 1 522 29.5 64.6 0.44 47.6 
Depression score 2-3 584 30.9 64.6 0.44 48.4 
Depression score 4-10 308 30.9 61.7 0.45 50.1 
Depression (continuous)  2389 29.5 0.034 63.1 0.174 0.44 0.013 47.9 <0.001 
          Work 
         manual work 1299 30.2 
0.127 
63.1 
0.025 
0.45 
0.643 
47.9 
0.009 
non-manual work 1090 28.2 66.1 0.45 46.8 
          Material conditions 
         low 908 31.6 
0.022 
63.1 
0.105 
0.45 
0.017 
49.0 
0.007 medium 521 30.2 63.1 0.44 46.8 
high 960 28.2 64.6 0.44 46.8 
          Years full time education 
         <12 years 669 30.9 
0.273 
63.0 
0.008 
0.45 
0.213 
49.0 
0.003 12-14 years 793 28.2 62.5 0.44 47.9 
15+ years 927 29.5 66.1 0.44 46.8 
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Table 4 Multivariate adjusted hazard ratios (95% Confidence Intervals) for all-cause mortality with depressive symptoms with univariate addition of 
biomarkers. Models are adjusted for social risk factors (work type, material condition, education), lifestyle factors (systolic blood pressure, lifetime smoking, 
alcohol, history of diabetes at baseline, BMI and HDL cholesterol. Biomarkers given in continuous form represent a 1 unit increase in the logarithm of each 
biomarker (equivalent to a x10 increase in the untransformed biomarker) and the untransformed biomarker in quartile divisions with quarter 1 the 
reference category. All-cause mortality based on 418 deaths in 18 years of follow up. Percentage of mediating effect of depressive symptoms explained by 
biomarker is calculated based on the log transformed continuous form of the biomarker.   
 
HR (95% C.I.) 
associated with 
1 unit increase 
in depressive 
symptoms 
HR (95% C.I.) associated with biomarker 
Percentage of 
age, social, 
lifestyle 
adjusted effect 
of depressive 
symptoms 
explained by 
biomarker 
per 1 log unit 
increase of 
biomarker Q 1 Quarter 2 Quarter 3 Quarter 4 
+ age 1.14 (1.08, 1.19) 
      + social risk factors 1.12 (1.06, 1.17) 
     
 + lifestyle risk 
factors 1.10 (1.04, 1.16) 
 + CRP  1.09 (1.04, 1.15 1.43 (1.13, 1.82) ref  0.98 (0.71, 1.37) 1.34 (0.98, 1.82) 1.47 (1.08, 2.01) 7.3% 
+ IL18  1.10 (1.04, 1.16) 1.06 (0.55, 2.02) ref  0.81 (0.60, 1.09) 0.96 (0.72, 1.28) 0.97 (0.73, 1.30) 0.0% 
+ IL1Ra 1.09 (1.04, 1.15) 2.10 (1.28, 3.40) ref  1.03 (0.75, 1.42) 1.23 (0.91, 1.67) 1.40 (1.04, 1.91) 5.2% 
+ Neopterin 1.09 (1.04, 1.15) 2.19 (0.93, 5.22) ref  1.06 (0.75, 1.49) 1.20 (0.88, 1.64) 1.27 (0.91, 1.77) 3.1% 
+ NTProBNP  1.09 (1.04, 1.15) 1.70 (1.33, 2.18) ref  1.08 (0.79, 1.48) 1.18 (0.87, 1.60) 1.71 (1.27, 2.29) 7.3% 
+ MRProANP  1.10 (1.04, 1.16) 1.97 (1.03, 3.77) ref  1.10 (0.80, 1.52) 1.17 (0.84, 1.63) 1.43 (1.04, 1.98) 6.3% 
+ MRProADM 1.09 (1.04, 1.15) 5.36 (1.30, 22.1) ref  1.20 (0.84, 1.71) 1.34 (0.94, 1.90) 1.53 (1.06, 2.22)  7.3% 
+ CTProET  1.09 (1.03, 1.15) 5.48 (1.36, 22.0) ref  0.81 (0.57, 1.15) 1.01 (0.72, 1.42) 1.29 (0.95, 1.77) 9.4% 
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Table 5 Multivariate adjusted hazard ratios (95% confidence Intervals) describing the association between depressive symptoms and all-cause mortality 
(418 cases). The model shows the hazard ratios and p values for relationships between socioeconomic, lifestyle and biomarker variables, upon successive 
adjustment with some variables not reaching significance in the final model.    
 
 
 
 
 
 
Variable HR (95% C.I.) P value HR (95% C.I.) P value HR (95% C.I.) P value HR (95% C.I.) P value 
Age 1.16 (1.12, 1.21) 0.001 1.16 (1.13, 1.22) 0.001 1.16 (1.11, 1.19) 0.001 1.15 (1.11, 1.19) 0.001 
depression 1.13 (1.08, 1.19) 0.001 1.11 (1.06, 1.17) 0.001 1.10 (1.04, 1.16) 0.001 1.09 (1.04, 1.15) 0.001 
work type 
  
0.71 (0.56, 0.89) 0.004 0.79 (0.62, 0.99) 0.048 0.8 (0.63, 1.008) 0.058 
material condition 
  
0.88 (0.78, 0.98) 0.024 0.95 (0.83, 1.06) 0.344 0.95 (0.85, 1.06) 0.412 
education 
  
0.92 (0.80, 1.05) 0.193 0.94 (0.83, 1.08) 0.425 0.94 (0.82, 1.07) 0.422 
history of diabetes 
    
2.11 (1.30, 3.42) 0.002 1.99 (1.22, 3.23) 0.005 
lifetime smoking 
    
1.33 (1.22, 1.44) 0.001 1.30 (1.19, 1.43) 0.001 
alcohol 
    
1.07 (1.01, 1.15) 0.043 1.07 (1.01, 1.15) 0.036 
systolic BP 
    
1.01 (1.01, 1.02) 0.001 1.01 (1.01, 1.01) 0.001 
HDLcholesterol 
    
1.12 (0.82, 1.54) 0.456 1.19 (0.87, 1.64) 0.257 
BMI 
    
0.85 (0.72, 0.99) 0.042 0.82 (0.69, 0.96) 0.014 
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Physical activity 
    
0.98 (0.87, 1.11) 0.755 0.98 (0.87, 1.11) 0.813 
CRP            1.43 (1.13, 1.80) 0.003 
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DISCUSSION 
Our study found that depressive symptoms were associated with all-cause mortality, but 
inflammatory and neurohormonal biomarkers are only weak mediators of this relationship. . The 
inflammatory markers CRP, IL1Ra and neurohormonal biomarkers NTProBNP, MRProANP, 
MRProADM and CTProET are associated with depressive symptoms and may play some additive role 
in the association between depressive symptoms and all-cause mortality  after adjustment for age, 
socioeconomic and lifestyle factors. Our results provide tentative support for the hypothesis that 
these biomarkers are involved in the biological domain of the pathway to depression, and warrant 
further study in larger longitudinal cohorts, and with greater levels of depressive symptoms. The 
discussion will (i) place these findings in context, (ii) identify further research questions suggested by 
the results, and (iii) highlight possible limitations.  
Biomarkers, depression and all-cause mortality 
Men in the PRIME Belfast study generally have low levels of depressive symptoms, with 13.8% of 
middle-aged men with scores in the range 4-10 of the 10-item modified Welsh depression score, 
which are consistent with previous findings from this cohort.[3, 13]  Similar levels of depressive 
symptoms have been reported using the CES-D scale in older (13.2%) and elderly (21.5%) general 
populations from Europe [Beekman et al.]1[20]. The method of measuring depressive symptoms and 
analysing them in relation to endpoints can strongly affect results.[3] CRP and IL1Ra have been 
reliably associated with depression in prospectively followed cohorts.[13, 20-21] Our estimates of a 
weak association between CRP, IL1Ra and depressive symptoms are similar to previous estimates 
[20-21, Vaccarino et al. 2007] and for CRP are comparable to the French PRIME estimates of its 
effect on depression and coronary heart disease.[13] Despite doubt surrounding the measurement 
of socioeconomic and occupational factors between the two countries, the relationship between 
CRP and depressive symptoms on outcomes is comparable in both studies [13]. BMI is a potential 
mediating factor between CRP, IL1Ra and MRProADM and depressive symptoms. Previous studies on 
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CRP and depressive symptoms corroborate BMI’s mediating link (Howren et al. 2009, Ma et al. 2011, 
Copeland et al. 2012). IL1 (and its derivative IL1Ra), IL6 and thus CRP and MRProADM may be 
secreted by adipose tissue/adipocytes potentially leading to an increased inflammatory response 
(Howren et al 2009). Neopterin has been associated with clinical depression, melancholia and 
chronic fatigue,[22] but while we observed a dose response relationship between depression and all 
three biomarkers measured at baseline, neopterin was not significantly related to all-cause mortality 
in contrast to the other two biomarkers. These biomarkers represent different stages in the 
inflammatory process, neopterin representing a cell-based immune response that may be related to 
more specific types of depression, while inflammatory regulators such as CRP and IL1Ra have been 
associated with atypical depression subtypes related to psychosocial stress [23] which may be more 
common in our sample. While these biomarkers may not be specific to depression but also related 
to other cardiovascular disease, recent meta-analysis has demonstrated beneficial effects of anti-
inflammatory drug treatment on depressive symptoms [Kohler et al. 2015]. This emphasises the 
importance of searching for novel biomarkers/underlying cellular mechanisms to support the 
identification of subgroups which could benefit from this treatment. Neurohormonal biomarkers 
NTProBNP, MRProADM and CTProET were associated with depressive symptoms and all-cause 
mortality in the prospective analysis. NTProBNP is reported to be weakly correlated with the 
neurohormones epinephrine (r2=0.17) and norepinephrine (r2=0.33) which are standard markers of 
psychosocial stress [6]. NTProBNP has previously been associated with major depression [], and 
correlated with depressive symptoms in healthy populations [Politi et al. 2007, Michel et al. 2014], 
and those with CVD [van der Broek et al. 2011] and diabetes [9].  Previous research has indicated a 
possible role of MRProADM with major depression [7] and bipolar disorders [8]. CTProET has not 
previously been associated with depression but has been linked to low socioeconomic status [24] 
and psychosocial stress associated with cardiovascular disease.[25] However up to 26% missing data 
was observed for MRProANP, MRProADM and CTProET which makes our estimates less precise but 
our study appears to be the first to examine the effect of these biomarkers on depressive symptoms 
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and mortality. Individually, inflammatory and neurohormonal biomarkers explain only a small 
proportion (0-9%) of the biological association between depressive symptoms and mortality in our 
dataset.  As these estimates were small and could in part, be accounted for by the large sampling 
variability, we did not calculate confidence bounds.  
Further research questions 
The biomarkers represent several stages in the inflammatory and neurohormonal process impacting 
on the HPA axis. From our data, it is not possible to establish the direction of causation, whether 
biomarkers have led to depression, or depression leads to increased levels of biomarkers. Wium-
Andersen et al. 2014 recently demonstrated that CRP is not causally related to depression using 
Mendelian randomisation.[26] They showed that while CRP was elevated in those with depression, 
genetically elevated CRP was not. Duvuis et al. also concluded depression increased CRP 
unidirectionally.[Duvuis et al. 2011]. Copeland et al. 2012 [27] examined CRP and depression using 
serial measurements at several time points over 6 years and also concluded that depression resulted 
in increased CRP levels which bidirectionally activates the stress response system. Depression is a 
clinically heterogeneous condition which can mask this stress response system and hinder efforts to 
identify its complex biological basis. Chronic exposure to psychosocial stress results in "wear and 
tear" on physiological systems, an effect described as allostatic load [5] which is difficult to capture 
in the general population. Disregulation of stress hormones and cytokines in response to stress can 
result in gradual overcompensation by other systems (e.g. metabolic) contributing to allostatic 
load.[28] Chronic psychosocial stress mediated through socioeconomic disadvantage via the putative 
biological mechanism of allostatic load has been linked to disease.[29] This putative mechanism 
inferred by our observed associations requires further investigation in larger studies with higher 
levels of depressive symptoms, repeated measures of depression and biomarkers would allow more 
detailed insight into the biological trends inferred from this work.     
Study strengths and limitations 
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Prospective studies examining the association between depression, biomarkers and health 
outcomes are limited, so our study provides useful information on a range of novel biomarkers 
several of which have never been studied in this context before, and insights into the underlying 
biological pathway involved between depressive symptoms and mortality. We have excluded men 
with CVD at baseline, reducing the possibility that pre-existing chronic illness explained the 
association between depressive symptoms, biomarkers and outcomes. We have adjusted for a wide 
range of variables which may confound the association between biomarkers and depression. 
However we are not able to adjust for medication use, and acknowledge that anti-inflammatory 
medicines, antidepressants and statins may affect inflammatory variables. Limitations of the study 
include low levels of depressive symptoms, and modest statistical power to detect small effects on 
outcome events.  The single baseline measurement of both depressive symptoms and biomarkers 
also limits our ability to assess whether depression precipitated or was preceded by an inflammatory 
or neurohormonal response in addition to a more formal mediation analysis. Further causal 
mediation analysis would be desirable when suitable methods for survival data are implemented2 
Conclusions 
] In a healthy middle-aged male cohort, inflammatory and neurohormonal biomarkers do not 
mediate the effect of depression on mortality but may play an additive role with depressive 
symptoms which could worsen the prognosis of the individual.  
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